Huai Qing, Mazar Andrew P, Kuo Alice, Parry Graham C, Shaw David E, Callahan Jennifer, Li Yongdong, Yuan Cai, Bian Chuanbing, Chen Liqing, Furie Bruce, Furie Barbara C, Cines Douglas B, Huang Mingdong
Division of Hemostasis and Thrombosis, Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
Science. 2006 Feb 3;311(5761):656-9. doi: 10.1126/science.1121143.
The urokinase plasminogen activator binds to its cellular receptor with high affinity and initiates signaling cascades that are implicated in pathological processes including tumor growth, metastasis, and inflammation. We report the crystal structure at 1.9 angstroms of the urokinase receptor complexed with the urokinase amino-terminal fragment and an antibody against the receptor. The three domains of urokinase receptor form a concave shape with a central cone-shaped cavity where the urokinase fragment inserts. The structure provides insight into the flexibility of the urokinase receptor that enables its interaction with a wide variety of ligands and a basis for the design of urokinase-urokinase receptor antagonists.
尿激酶型纤溶酶原激活剂以高亲和力与其细胞受体结合,并启动与包括肿瘤生长、转移和炎症在内的病理过程相关的信号级联反应。我们报道了与尿激酶氨基末端片段及抗该受体抗体复合的尿激酶受体的1.9埃晶体结构。尿激酶受体的三个结构域形成一个带有中央锥形腔的凹面,尿激酶片段插入该腔中。该结构为尿激酶受体的灵活性提供了见解,这种灵活性使其能够与多种配体相互作用,并为设计尿激酶-尿激酶受体拮抗剂奠定了基础。